Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 15;14:214. doi: 10.3389/fncel.2020.00214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Papon, Le Feuvre, Barreda-Gómez, Favereaux, Farrugia, Bouali-Benazzouz, Nagy, Rodríguez-Puertas and Landry.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Fibulin-2 controls the sensitivity to baclofen and saclofen of GABAB-mediated presynaptic inhibition. (A1) Spontaneous miniature EPSCs (mEPSCs) recorded from cultured spinal neurons transfected with mismatch siRNA before and after application of baclofen (10 μM) and baclofen + saclofen (100 μM). (A2) Amplitude cumulative probability for the experiment shown in (A1). Inset trace shows superimposed average of 25 mEPSCs obtained in control and in presence of baclofen. (A3) Inter-event interval cumulative probability for the experiment shown in (A1). The distribution is significantly shifted toward the right during baclofen application. (A4,A5) average variation in mEPSC amplitude (A4) and frequency (A5), expressed as percent of control (n = 9). (B1) mEPSCs recorded from cultured spinal neurons transfected with fibulin-2 siRNA before and after application of baclofen (10 μM), saclofen (100 μM), and CGP (50 μM). (B2) Amplitude cumulative probability for the experiment shown in (B1). Inset trace shows superimposed average of 25 mEPSCs obtained in control and in presence of baclofen. (B3) Inter-event interval cumulative probability for the experiment shown in (B1). The distribution is shifted toward the right during baclofen and baclofen + saclofen application. (B4,B5) Average variation in mEPSC amplitude (B4) and frequency (B5), expressed as percent of control (n = 7). (C1,C2) Average frequencies (C1) and amplitudes (C2) of mEPSCs recorded in preparations transfected with mismatch (n = 9) or anti fibulin-2 siRNA (n = 7), in control conditions and in the presence of baclofen (10 μM).